Ceclor
(Cefaclor)ApprovedSmall molecule
Eli LillyCeclor is one of 22 small molecule programs targeting Endocarditis. It is currently in Approved.
2
Indications
1
Total Trials
1
Active Trials
21
Competitors
3
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
17 competitors in Infective Endocarditis
#DrugCompanyPhaseTrials
1Zyvox
PfizerApproved
Rifadin
SanofiApproved
Cipro
BayerApproved
Avelox
BayerApproved
Acanya
PfizerApproved
Vancocin
HHikma Pharmaceuticals LLC
Approved
Cubicin
BBaxter Healthcare Corporation
Approved
Alka-Seltzer
AAbbott
Approved
Levaquin
WWim Janssens
Approved
Amoxil
GGlobal Antibiotics Research and Development Partnership
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Regulatory
FDA Approval Timeline[4]
Jan 1, 1982
CECLOR
NDA NDA050521
Jan 1, 1982
CECLOR
NDA NDA050522
Jun 28, 1996
CECLOR CD
NDA NDA050673
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Cefaclor. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]